{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"81.81","value":"430.6"},{"groupId":"OG001","spread":"46.33","value":"470.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"252"}],"units":"Participants"}],"title":"Day 22, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"77.16","value":"430.1"},{"groupId":"OG001","spread":"46.23","value":"486.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"221"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"Day 22, 1-hour post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"71.08","value":"401.0"},{"groupId":"OG001","spread":"53.67","value":"404.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"206"},{"groupId":"OG001","value":"252"}],"units":"Participants"}],"title":"Day 43, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"69.97","value":"401.6"},{"groupId":"OG001","spread":"54.48","value":"425.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"208"},{"groupId":"OG001","value":"252"}],"units":"Participants"}],"title":"Day 43, 1-hour post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.85","value":"457.0"},{"groupId":"OG001","spread":"52.81","value":"475.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"195"},{"groupId":"OG001","value":"239"}],"units":"Participants"}],"title":"Day 43, 2-hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"55.41","value":"525.8"},{"groupId":"OG001","spread":"46.75","value":"546.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"192"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"title":"Day 43, 4-hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.51","value":"544.3"},{"groupId":"OG001","spread":"45.28","value":"549.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"187"},{"groupId":"OG001","value":"237"}],"units":"Participants"}],"title":"Day 43, 6-hours post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"59.73","value":"393.7"},{"groupId":"OG001","spread":"53.87","value":"372.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"227"}],"units":"Participants"}],"title":"Day 106, pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.12","value":"407.6"},{"groupId":"OG001","spread":"54.56","value":"380.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"148"},{"groupId":"OG001","value":"223"}],"units":"Participants"}],"title":"Day 106, 1-hour post-dose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"244"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"An analysis will be performed to assess whether the plasma concentration of osimertinib is affected when given with or without chemotherapy. Samples were collected pre-dose and 1-hour post-dose on day 22 and day 106; on day 43 samples were collected pre-dose and 1-, 2-, 4-, and 6-hours post-dose.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Osimertinib (AZD9291) 80 mg in combination with pemetrexed (500 mg/m2) plus either cisplatin (75 mg/m2) or carboplatin (AUC5) on Day 1 of 21-day cycles for 4 cycles, followed by Osimertinib (AZD9291) 80 mg QD with Pemetrexed maintenance (500 mg/m2) Q3W","id":"OG000","title":"Randomized: AZD9291 + Chemo"},{"description":"Osimertinib (AZD9291) 80mg QD.","id":"OG001","title":"Randomized: AZD9291"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic Analysis Set, includes all randomized participants that received at least 1 dose of study treatment, have at least 1 measurable PK concentration and no missing doses 7 days prior to the PK sample, without any protocol deviation that affects PK, supported by the relevant date and time of this sample.","reportingStatus":"POSTED","timeFrame":"Pre-dose and 1-hour post-dose on Day 22; pre-dose, 1-, 2-, 4-, and 6-hours post-dose on Day 43; pre-dose and 1-hour post-dose on Day 106.","title":"Plasma Concentration of Osimertinib When Given With or Without Chemotherapy (Randomized Component)","type":"SECONDARY","unitOfMeasure":"nM"}